2019
EPID-29. THE INFLUENCE OF SOCIOECONOMIC FACTORS AND CANCER CARE RECEIVED AT DIFFERENT FACILITIES ON OUTCOME IN PATIENTS WITH GLIOBLASTOMA
Li T, Patel P, Chou J, Patel A, Crispo S, Utate M, Kurz S. EPID-29. THE INFLUENCE OF SOCIOECONOMIC FACTORS AND CANCER CARE RECEIVED AT DIFFERENT FACILITIES ON OUTCOME IN PATIENTS WITH GLIOBLASTOMA. Neuro-Oncology 2019, 21: vi80-vi81. PMCID: PMC6847338, DOI: 10.1093/neuonc/noz175.329.Peer-Reviewed Original ResearchComprehensive cancer centerInsurance statusCancer careCity HospitalHealthcare system-related factorsNCI-designated comprehensive cancer centerUtilization of healthcareSystem-related factorsInfluence of socioeconomic factorsYounger ageHealthcare disparitiesCare facilitiesSocial supportInfluence outcomesMedian overall survivalUninsured patientsMarital statusZip codesSocioeconomic factorsPatient informationSocioeconomic classCareMedian incomeRetrospective observational studyCancer Center
2018
PD-1 inhibition has only limited clinical benefit in patients with recurrent high-grade glioma.
Kurz S, Cabrera L, Hastie D, Huang R, Unadkat P, Rinne M, Nayak L, Lee E, Reardon D, Wen P. PD-1 inhibition has only limited clinical benefit in patients with recurrent high-grade glioma. Neurology 2018, 91: e1355-e1359. PMID: 30171077, DOI: 10.1212/wnl.0000000000006283.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBevacizumabBrain NeoplasmsFemaleGliomaHumansMaleMiddle AgedNeoplasm Recurrence, LocalNivolumabProgrammed Cell Death 1 ReceptorRetrospective StudiesSalvage TherapySurvival AnalysisTreatment OutcomeYoung AdultConceptsRecurrent high-grade gliomaHigh-grade gliomasRetrospective observational studySalvage therapySurvival benefitSingle-institution retrospective observational studyPD-1 blocking antibodiesObservational studyPD-1 inhibitionProgression-free survivalClass IV evidenceConcurrent bevacizumabAntibody nivolumabPD-1Median survivalClinical benefitImproved survivalNivolumabPembrolizumabAdult patientsBevacizumabIV evidenceClinical trialsPatient populationPatients